WeVote
Log In

Bill

Bill

HR 7867

Infant Formula Safety Modernization Act of 2026

119th Congress Introduced by Sanford Bishop and 37 co-sponsors

HR 7867 mandates standardized pathogen testing of infant formula and facilities with required notification of positive results to strengthen FDA safety oversight.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 7867

Legislative bill overview

HR 7867 would establish mandatory standardized testing protocols for pathogens and microorganisms in infant formula products and manufacturing facilities under FDA oversight. The bill requires notification of positive test results and inspection classification details, strengthening regulatory oversight of infant formula safety from production through distribution.

Why is this important

Infant formula is a critical nutritional source for infants who cannot breastfeed, making contamination risks particularly serious given infants' vulnerable immune systems. Recent contamination incidents (notably the 2022 Abbott facility closure) exposed gaps in testing consistency and transparency, prompting calls for standardized protocols to prevent future public health crises.

Potential points of contention

  • Regulatory burden and costs: Manufacturers may argue standardized testing across all facilities increases operational costs, potentially affecting pricing or market entry for smaller producers
  • Testing standard specificity: Disagreement could arise over which pathogens/microorganisms require testing, thresholds for action, and whether standards align with international practices or impose uniquely stringent U.S. requirements
  • Notification transparency vs. market panic: Balancing public notification of positive tests against potential consumer panic or market disruption; debate over disclosure timing and detail level

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.